You are here: Industry Insights > Enhertu

News List

Enhertu improves progression-free survival in breast cancer trial pharmatimes
August 09, 2021
Positive topline results from a Phase III trial for Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu have shown that the HER2-directed antibody drug conjugate (ADC) ADC demonstrated superiority over trastuzumab emtansine (T-DM1).
Enhertu accepted via cancer drugs fund for HER2-positive breast cancer pharmatimes
April 21, 2021
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu for use within the cancer drugs fund (CDF) for the treatment of previously-treated HER2-positive metastatic breast cancer.
AZ, Daiichi Sankyo’s Enhertu scores approval in the UK pharmatimes
February 19, 2021
AstraZeneca (AZ) and Daiichi Sankyo’s antibody drug conjugate (ADC) Enhertu has scored a conditional marketing authorisation in the UK for certain breast cancer patients.
AZ/Daiichi Sankyo’s antibody drug conjugates prove promising in early trials pharmatimes
January 29, 2021
AstraZeneca (AZ) and Daiichi Sankyo have posted new data from Phase I/II trials evaluating their respective antibody drug conjugates (ADCs) Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan.
Enhertu bags EU approval for HER2-positive breast cancer pharmatimes
January 21, 2021
AstraZeneca and Daiichi Sankyo’s HER2-targeting antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has been granted a conditional approval in the EU.
AZ, Daiichi Sankyo’s Enhertu wins US approval for HER2-positive gastric cancer pharmatimes
January 19, 2021
AstraZeneca and Daiichi Sankyo’s HER2-targeting antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval in the US for the treatment of locally advanced/metastatic HER2-positive gastric or gastroesophageal junction (GEJ) ...
Enhertu scores ‘impressive’ new data in HER2 breast cancer pharmatimes
December 11, 2020
AstraZeneca (AZ) and Daiichi Sankyo have reported updated results from a phase II trial of Enhertu, which continued to demonstrate ‘impressive’ efficacy in patients with HER2-positive metastatic breast cancer.
Enhertu bags US priority review for HER2 gastric cancer pharmatimes
October 29, 2020
AstraZeneca’s Enhertu has scored a priority review from the US Food and Drug Administration (FDA) for the treatment of HER2-positive metastatic gastric cancer.
Enhertu granted orphan drug designation in US for gastric cancer pharmaceutical-business-review
May 28, 2020
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has been granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.
AstraZeneca gets breakthrough status for Enhertu to treat NSCLC pharmaceutical-technology
May 20, 2020
AstraZeneca and its partner Daiichi Sankyo have received breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for Enhertu (trastuzumab deruxtecan) to treat non-small cell lung cancer (NSCLC).

Previous page 1 2 Next page